Clear Street raised the firm’s price target on Oruka Therapeutics (ORKA) to $71 from $46 and keeps a Buy rating on the shares. The firm says the Phase 1 data for ORKA-002 in hidradenitis suppurativa hit the bull case. It sees “best-in-class” potential for the drug.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka Therapeutics: Long-Acting IL-17 Platform Drives Upgraded Valuation and Buy Rating
- Oruka provides updates on Phase 1 trial of ORKA-002, EVERLAST-B ORKA-001 trial
- Oruka Therapeutics initiated with a Buy at UBS
- ORKA-001 Psoriasis Trial: Fresh Phase 2 Update and What It Means for Investors
- Oruka Therapeutics initiated with an Overweight at Piper Sandler